The Boeing Company (NYSE:BA) reported Q3 earnings and revenue that beat the analyst estimates while fiscal 2014 earnings guidance was raised. Boeing reports Q3 earnings were up 19% to $2.14 as revenue increased 7% to $23.8 billion whereas the Street expected $1.96 per share on revenue of $23.0 billion, according to Capital IQ estimates. For 2014, The Boeing Company (NYSE:BA) expects $8.10 to $8.30, a $0.20-per-share increase from the previous range. The Street expects earnings of $8.08 for fiscal 2014. Revenue is seen at $87.5 to $90.5 billion, in line with expectations of $89.6 billion. BA trades in a 52-week range of $116.32 to $144.57 with shares up 2.5% at $130.49.Boston Scientific Corporation (NYSE:BSX) a medical technology company, reported Q3 results that were in line with the Street view on EPS but beat expectations on total revenues. The company reported Q3 EPS of $0.20, up from $0.17 in Q3 2013 and in line with analyst estimates of $0.20. Total revenues of $1.84 billion were up from $1.73 billion in Q3 2013 and topped analyst projections of $1.81 billion for the quarter.The company reported Q3 revenue growth of 8% in its Cardiovascular segment, 7% in Rhythm Management, and 5% over the prior year period. Boston Scientific Corporation (NYSE:BSX) now estimates revenue for the full year 2014 to be in a range of $7.37 to $7.42 billion, up from prior guidance of $7.32 to $7.42 billion, and adjusted earnings in a range of $0.81 to $0.83 per share, up from prior guidance of $0.79 to $0.83. The company estimates sales for Q4 in a range of $1.875 to $1.925 billion and adjusted earnings in a range of $0.20 to $0.22 per share. Shares of BSX are at $12.03 within a 52-week range of $11.10 - $14.08.Biogen Idec Inc (NASDAQ:BIIB) reported Q3 earnings that exceeded analysts' estimates and also raised its FY EPS guidance to exceed views while sales were in line with the Street's consensus. Biogen Idec Inc (NASDAQ:BIIB) is trading within the 52-week range between $230.25 and $358.89. The biotechnology company said Q3 non-GAAP diluted earnings rose 61% to $3.80 per share, exceeding the $3.46 average estimate from analysts polled by Capital IQ. Sales jumped 37% to $2.51 billion compared to the $2.48 billion consensus estimate.Reported net income rose to $856,9 million or $3.62 per diluted share from $487.6 million or $2.05 per share. For FY 2014, Biogen Idec said it still expects revenue growth between 38% and 41% from 2013 while non-GAAP diluted EPS is now expected to be between $13.45 and $13.55, up from the previous guidance range between $12.90 and $13.10, and exceeding analysts' $13.10 average estimate.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
